Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States.
Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata.
Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Jodie Morrison |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 999 0232 |
| Website | q32bio.com |
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661998 |
| ISIN Number | US7469641051 |
| Employer ID | 47-3468154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer and Director |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer and President of Research |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer |
| Lee H. Kalowski M.B.A. | Chief Financial Officer and President |
| Dr. Saul Fink Ph.D. | Chief Technology Officer |
| David Appugliese J.D. | Senior Vice President and Head of People |
| Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy and Program Operations |
| Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 424B3 | Prospectus |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 424B3 | Prospectus |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 9, 2024 | 424B3 | Prospectus |